Clinical Trial Update: A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS) [Phase 1]

View source ↗

Summary

A Phase 1 safety and tolerability study of PF-06342674 (RN168) in individuals with Multiple Sclerosis was terminated; results were posted on 2017-01-16.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• PF-06342674 (RN168) (PF-06342674)

Snippet

Sponsor: Pfizer | Conditions: Multiple Sclerosis | Phase 1 | Status: TERMINATED | Results posted: 2017-01-16